Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.81), $0.58 worse than the analyst estimate of ($1.23). Revenue for the quarter came in at $160 million versus the consensus estimate of $167 million.

GUIDANCE:

Ultragenyx Pharma sees FY 2025 revenue of $640-670 million, versus the consensus of $657.4 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.